Boehringer Ingelheim & Trupanion Announce Exclusive Collaboration to Increase Access to Pet Care
SEATTLE, June 12, 2024--(BUSINESS WIRE)--Trupanion, Inc. (Nasdaq: TRUP), the leading provider of medical insurance for cats and dogs in North America, and Boehringer Ingelheim, one of the largest innovators in animal disease prevention and treatment globally, today announced a strategic collaboration to provide pets and their families increased access to high-quality healthcare and enhanced disease treatment and protection.
Both companies have strong commitments to caring for pets throughout their lifetime. This collaboration will allow them to leverage their collective expertise and data to derive insights which will enable the early detection of risk factors for common conditions affecting pets. Ultimately, this will support earlier detection and better management of diseases. The two companies will work together on continuing veterinarian and consumer education, product extensions, promotions, peer-reviewed publications, and other efforts in support of pet healthcare.
"We are excited to work with Trupanion because they are so closely aligned with our mission of creating a world where pets and those who care for them thrive," said Daniel Watkins, who leads the Boehringer Ingelheim Pet business. "Our dedication to driving industry-leading advancements in animal disease treatments and prevention is a perfect complement to Trupanion’s best-in-class product, which increases access to exceptional care and helps pet caregivers protect their beloved pets throughout their life. By working together, we will open new doors in the animal health industry for the veterinary community and pet owners alike."
This collaboration means that when a pet is enrolled with Trupanion, their families will be able to opt in to receive dedicated information and support from Boehringer to help them manage their pet’s health in the best possible way. In addition, Boehringer will look to support Trupanion’s goal of ensuring all pets receive the best medical care possible through its vast veterinary relationships. Boehringer Ingelheim and Trupanion are both fully committed to supporting veterinarians, pets and their families through every step of their lifetime of care.
Trupanion's market-leading growth stems from the difference it brings to the industry and its solution for unexpected costs of care. As the only pet medical insurance provider able to pay veterinarians directly at checkout in seconds, Trupanion eliminates the need for pet parents to submit a claim and wait for reimbursement. This allows families and veterinary hospitals to focus on pursuing the best treatment options instead of financial hurdles. With unlimited payouts for life, unique lifetime pricing, and 24/7/365 live support, Trupanion provides families and their pets with support when they need it most and has proudly paid nearly $3 billion in veterinary invoices on behalf of its members. With inflation, human-quality medical advancements, and other factors spurring historic increases to the cost of veterinary care, the need for high-quality, comprehensive medical insurance for pets has never been greater.
"We're thrilled and humbled that Boehringer chose us as a partner. With this relationship, lifetime care meets lifetime coverage at a time when pet parents need us more than ever," said Dr. Steve Weinrauch, BVMS, MRCVS, Chief Veterinary and Product Officer at Trupanion. "We couldn’t be more excited for the new ways we’ll be able to support pets, pet parents and the veterinary community through this collaboration moving forward."
About Boehringer Ingelheim Animal Health USA
Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock.
As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long-term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both.
About Trupanion
Trupanion is the leading provider of medical insurance for over 1,000,000 cats and dogs throughout the United States, Canada, Europe, Puerto Rico and Australia. For over two decades, Trupanion has given pet owners peace of mind so they can focus on their pet's recovery, not financial stress. With its patented process, Trupanion is the only North American provider with the technology to pay veterinarians directly in seconds at the time of checkout. Trupanion is listed on NASDAQ under the symbol "TRUP". The company was founded in 2000 and is headquartered in Seattle, WA. Trupanion policies are issued, in the United States, by its wholly-owned insurance entity American Pet Insurance Company and, in Canada, by Accelerant Insurance Company of Canada. Trupanion Australia is a partnership between Trupanion and Hollard Insurance Company. For more information, please visit trupanion.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to, among other things, expectations, plans, prospects and collaborative partnering efforts. These forward-looking statements are based upon current expectations and beliefs as of the date of this press release, and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described. In particular, development and execution of collaborative activity could be delayed or changed as efforts continue. For a detailed discussion of risks and uncertainties with respect to Trupanion and its business, please refer to the risk factors discussed in filings with the Securities and Exchange Commission (SEC), including but not limited to, Trupanion’s Annual Report on Form 10-K for the year ended December 31, 2023 and any subsequently filed reports on Forms 10-Q, 10-K and 8-K.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240612615100/en/
Contacts
Boehringer Ingelheim
Brett Israel
Director, PR and Communications, U.S. Pet
brett.israel@boehringer-ingelheim.com
Trupanion
Laura Bainbridge
Senior Vice President, Corporate Communications
Corporate.Communications@trupanion.com